Xylazine

Research use only, not for human use.

Xylazine is α2-adrenergic receptor agonist.

Xylazine is α2-adrenergic receptor agonist.

——

Xylazine (5.2 mg/kg; intraperitoneal injection; for 10-60 minutes; male Sprague-Dawley rats) administration alters mRNA expression and protein phosphorylation levels of AMPK signaling molecules, suggesting that the LKB1-AMPK pathway plays a role in the sedative and tranquilizing effects in the CNS caused by Xylazine treatment. Animal Model:Male Sprague-Dawley rats (160-180 g)Dosage:5.2 mg/kg Administration:Intraperitoneal injection; for 10 minutes, 20 minutes, 40 minutesor 60 minutes Result:Increased in AMPK activity in the cerebral cortex, hippocampus, thalamus and cerebellum. Phosphorylated LKB1 and AMPKα protein levels were decreased.

BAY 1470

Metabolic Enzyme/Protease

P450

α2-adrenergic receptor

Neurological Disease

——

7361-61-7

220.33

C12H16N2S

>98% (HPLC)

——

Cc1cccc(C)c1NC1=NCCCS1

——

(-20℃)

With Ice Pack

≥ 2 years